Gilead Sciences, Inc. announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex® for the treatment of adults with chronic hepatitis delta infection.
Gilead Sciences, Inc. announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex® for the treatment of adults with chronic hepatitis delta infection.